Urinary incontinence is a widely prevalent condition, affecting 1 in 3 women. Although a very private concern, it has far-reaching physical, social, and economic implications, with annual costs to the US healthcare system approaching $25 billion. Elidah is developing a non-surgical treatment for mild to moderate stress urinary incontinence (SUI) sufferers. Through this wearable therapeutic device, Elidah will improve the quality of life and reduce the need for surgery for tens of millions of women. There are no medications that address SUI, surgery is a painful last resort, and exercises are difficult to perform and comply with. Although intravaginal electrical muscle stimulation (EMS) have proven clinically successful at retraining pelvic floor muscles, intravaginal probes presents psychological barriers, leading two thirds of affected women to quietly suffer without effective treatment. Clinical studies demonstrate that surface electrodes around the perineal region are just as effective, and so Elidah is developing a programmable, discreet surface EMS treatment that is comfortably administered while the patient goes about normal activity. The device is comprised of a tiny signal generator and a disposable electrode component. It is programmed through a docking station and/or mobile app, and usage data is optionally transmitted to a physician, a practice shown to significantly increase patient compliance. The team is composed of medical device engineers and entrepreneurs from MIT, Stanford and RPI, with 35 combined years of product development and commercialization experience, with specific expertise in urology and wearable therapeutics.